Argenx SE

Janus Henderson’s Global Sustainable Equity Active ETF outperformed MSCI World in April 2026 by leveraging AI‑driven tech gains, underweighting weak energy and staples, and positioning for long‑term renewable growth.

Argenx SE’s earnings prompt revised analyst targets amid leadership shifts: solid 12% revenue growth, 28% margin, €115m cash flow, yet cautious valuations reflect market uncertainty yet strong pipeline optimism.

FDA approves Argenx’s Vyvgart for CIDP, expanding its neuro‑immune reach and unlocking a $1B+ market with proven efficacy and a solid safety profile.

Argenx’s expanded FDA approval of efgartigimod (VYVGART) for all adult generalized myasthenia gravis patients—irrespective of serotype—offers a broader, serotype‑agnostic treatment option, backed by Phase 3 data showing rapid, sustained symptom impr…

FDA expands VYVGART label to all adult generalized myasthenia gravis patients—evidence shows significant, sustained benefit across all serotypes, simplifying treatment and improving access.

Argenx SE’s share price jumped 12 % in the last year thanks to a strong antibody pipeline, growing revenue and better margins, but regulatory delays, clinical risk, and competition may temper this rally.

Argenx’s VYVGART shows rapid, durable relief for MG and CIDP patients, backed by phase‑III data and FDA priority review—redefining neuromuscular treatment options.

Argenx’s sustained share‑price growth hinges on Vyvgart’s CD28 blockade, offering a targeted immunotherapy for lupus and rheumatoid arthritis that could boost investor confidence at the 2026 AGM.

Argenx’s new Phase‑3 data shows VYVGART dramatically improves ocular and generalized myasthenia gravis and expands into CIDP and CMS, offering a potent, convenient SC option with a clear regulatory roadmap.

Argenx’s VYVGART expands into ocular and seronegative myasthenia gravis, showing strong Phase‑3 data and promising CIDP results—positioning the drug for a niche, high‑value market with lower competition.